<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">persmed</journal-id><journal-title-group><journal-title xml:lang="ru">Российский журнал персонализированной медицины</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Journal for Personalized Medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2782-3806</issn><issn pub-type="epub">2782-3814</issn><publisher><publisher-name>ФОНД АЛМАЗОВА</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18705/2782-3806-2023-3-3-108-117</article-id><article-id custom-type="elpub" pub-id-type="custom">persmed-167</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>РЕНТГЕНОЛОГИЯ И РАДИОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>RADIOLOGY</subject></subj-group></article-categories><title-group><article-title>Возможности использования ПЭТ/КТ с 11С-метионином в топической диагностике первичного гиперпаратиреоза</article-title><trans-title-group xml:lang="en"><trans-title>11С-methionine PET/CT use in the diagnosis of primary hyperparathyroisis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Погосян</surname><given-names>К. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Pogosian</surname><given-names>K. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Погосян Карина Александровна, младший научный сотрудник НИЛ нейроэндокринных опухолей</p><p>ул. Аккуратова, д. 2, Санкт-Петербург, 197341</p></bio><bio xml:lang="en"><p>Pogosian Karina A., MD, junior researcher of the Laboratory of Neuroendocrine Tumors</p><p>Akkuratova str., 2, Saint Petersburg, 197341</p></bio><email xlink:type="simple">karina.a.pogosyan@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Каронова</surname><given-names>Т. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Karonova</surname><given-names>T. L.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Каронова Татьяна Леонидовна, д.м.н., заведующий НИЛ новой коронавирусной инфекции и постковидного синдрома НЦМУ «Центр персонализированной медицины», главный научный сотрудник НИЛ клинической эндокринологии Института эндокринологии</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Karonova Tatiana L., MD, DSc, Head of New Coronavirus Infection and Postcovid Syndrome Laboratory </p><p>Saint Petersburg</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Рыжкова</surname><given-names>Д. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Ryzhkova</surname><given-names>D. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Рыжкова Дарья Викторовна, д.м.н., профессор, заведующий кафедрой ядерной медицины и радиационных технологий с клиникой Института медицинского образования</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Ryzhkova Daria V., MD, DSc, professor, Head of Department of Nuclear Medicine and Radiation Technology</p><p>Saint Petersburg</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Цой</surname><given-names>У. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Tsoy</surname><given-names>U. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Цой Ульяна Александровна, к.м.н., заведующий НИЛ нейроэндокринных опухолей</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Tsoy Uliana A., MD, PhD, Head of the Laboratory of Neuroendocrine Tumors in the Research Centre of Personalized Oncology</p><p>Saint Petersburg</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Семенова</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Semenova</surname><given-names>A. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Семенова Алиса Николаевна, ординатор 1 года по специальности «эндокринология»</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Semenova Alisa N., resident</p><p>Saint Petersburg</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Юдина</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Yudina</surname><given-names>O. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Юдина Ольга Васильевна, к.м.н., доцент кафедры ядерной медицины и радиационных технологий с клиникой Института медицинского образования</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Olga V. Yudina, MD, PhD, Associate Professor, Department of the Nuclear Medicine and Radiation Technology</p><p>Saint Petersburg</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гринева</surname><given-names>Е. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Grineva</surname><given-names>E. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гринева Елена Николаевна, д.м.н., профессор, директор Института эндокринологии</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Grineva Elena N., MD, DSc, professor, Director of the Institute of endocrinology</p><p>Saint Petersburg</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени В. А. Алмазова» Министерства здравоохранения Российской Федерации, Научный центр мирового уровня «Центр персонализированной медицины»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Almazov National Medical Research Centre, World-Class Research Centre for Personalized Medicine</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Федеральное государственное бюджетное военное образовательное учреждениевысшего образования «Военно-медицинская академия имени С. М. Кирова» Министерства обороны Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Military Medical Academy</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>28</day><month>07</month><year>2023</year></pub-date><volume>3</volume><issue>3</issue><fpage>108</fpage><lpage>117</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Погосян К.А., Каронова Т.Л., Рыжкова Д.В., Цой У.А., Семенова А.В., Юдина О.В., Гринева Е.Н., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Погосян К.А., Каронова Т.Л., Рыжкова Д.В., Цой У.А., Семенова А.В., Юдина О.В., Гринева Е.Н.</copyright-holder><copyright-holder xml:lang="en">Pogosian K.A., Karonova T.L., Ryzhkova D.V., Tsoy U.A., Semenova A.N., Yudina O.V., Grineva E.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://persmed.elpub.ru/jour/article/view/167">https://persmed.elpub.ru/jour/article/view/167</self-uri><abstract><sec><title>Актуальность</title><p>Актуальность. Первичный гиперпаратиреоз (ПГПТ) — эндокринное заболевание, характеризующееся автономной секрецией паратиреоидного гормона (ПТГ). Радикальным методом лечения ПГПТ является паратиреоидэктомия (ПТЭ), результат которой в большой степени зависит от точной визуализации аденомы околощитовидных желез (ОЩЖ) на предоперационном этапе. К традиционным методам топической диагностики ПГПТ относятся ультразвуковое исследование (УЗИ), сцинтиграфия, мультиспиральная компьютерная томография (МСКТ), каждый из них имеет свои ограничения. С целью улучшения диагностики применяют позитронно-эмиссионную томографию/компьютерную томографию (ПЭТ/КТ) с 11C-метионином.</p></sec><sec><title>Цель</title><p>Цель. Сравнить чувствительность и специфичность ПЭТ/КТ с 11С-метионином с аналогичными характеристиками традиционных методов визуализации аденом околощитовидных желез.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Были проанализированы данные 91 больного с диагнозом ПГПТ. УЗИ, сцинтиграфия с 99mTc-сестамиби/99mTc-пертехнетатом и МСКТ были выполнены 91, 56 и 86 пациентам соответственно. С 2020 года ПЭТ/КТ с 11C-метионином использовалась в качестве завершающего метода топической диагностики у 45 больных. Оценка диагностических характеристик визуализирующих методов проводилась на основании результатов гистологического исследования.</p></sec><sec><title>Результаты</title><p>Результаты. Гистологическое исследование подтвердило наличие аденомы/гиперплазии ОЩЖ у всех больных. Множественные аденомы/гиперплазии были обнаружены в 5 случаях. Эктопированные аденомы были выявлены у 19 больных. Чувствительность ПЭТ/КТ с 11C-метионином составила 98 %, МСКТ, сцинтиграфии и УЗИ — 75 %, 79 %, 67 % соответственно. Специфичность — 93 %, 73 %, 75 %, 70 % соответственно.</p></sec><sec><title>Заключение</title><p>Заключение. ПЭТ/КТ с 11C-метионином продемонстрировала более высокие показатели чувствительности и специфичности, чем традиционные методы визуализации аденом ОЩЖ.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Background</title><p>Background. Primary hyperparathyroidism (PHPT) is an endocrine disorder characterized by autonomous production of parathyroid hormone (PTH). Currently, parathyroidectomy (PTX) is considered the main method of PHPT treatment. Its outcome is largely depended on precise preoperative localization of the parathyroid adenoma. Traditional visualization techniques include ultrasound (US), scintigraphy and computed tomography (CT), each of which has its own limitations. In order to improve visualization results positron emission tomography/ computed tomography (PET/CT) with 11C-methionine is used. Objective. To compare the sensitivity and specificity of 11 C-methionine PET/CT with those of conventional imaging techniques for parathyroid adenomas localization.</p></sec><sec><title>Design and methods</title><p>Design and methods. The data of 91 patients diagnosed with PHPT was analyzed. Ultrasound, scintigraphy with 99mTc-sestamib i/99mTc-pertechnetate and CT were performed in 91, 56, and 86 patients, respectively. Since 2020, 11C-methionine PET/CT has been used as the final diagnostic method in 45 patients. Histologу results were used as the benchmark in order to evaluate the diagnostic accuracy of the studied methods.</p></sec><sec><title>Results</title><p>Results. Histological examination confirmed parathyroid adenoma/ hyperplasia in all patients. Multiple adenomas/hyperplasia were found in 5 cases. Ectopic adenomas were detected in 19 patients. The sensitivity of PET/CT with 11C-methionine was 98 %, CT, scintigraphy and ultrasound — 75 %, 79 %, 67 %, respectively. Specificity — 93 %, 73 %, 75 %, 70 %, respectively.</p></sec><sec><title>Conclusion</title><p>Conclusion. 11C-methionine PET/CT showed higher sensitivity and specificity than traditional methods.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>11C-метионин</kwd><kwd>мультиспиральная компьютерная томография</kwd><kwd>первичный гиперпаратиреоз</kwd><kwd>ПЭТ/КТ</kwd><kwd>сцинтиграфия</kwd><kwd>ультразвуковое исследование</kwd></kwd-group><kwd-group xml:lang="en"><kwd>11C-methionine</kwd><kwd>computed tomography</kwd><kwd>PET/CT</kwd><kwd>primary hyperparathyroidism</kwd><kwd>scintigraphy</kwd><kwd>ultrasound</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Работа выполнена при финансовой поддержке Министерства науки и высшего образования Российской Федерации (соглашение № 075-152022-301).</funding-statement><funding-statement xml:lang="en">The work was supported financially by the Ministry of Science and Higher Education of the Russian Federation (agreement No. 075-15-2022-301).</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Noltes ME, Coester AM, van der Horst-Schrivers ANA, et al. Localization of parathyroid adenomas using (11)C-methionine pet after prior inconclusive imaging. Langenbecks Arch Surg 2017;402:1109–17.</mixed-citation><mixed-citation xml:lang="en">Noltes ME, Coester AM, van der Horst-Schrivers ANA, et al. Localization of parathyroid adenomas using (11)C-methionine pet after prior inconclusive imaging. Langenbecks Arch Surg 2017;402:1109–17.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Walker MD, Bilezikian JP. Primary Hyperparathyroidism. Endotext [Internet]. South Dartmouth (MA); 2021 [updated 2021 Apr 19, cited 2022 Mar 28]. Available online: https://www.ncbi.nlm.nih.gov/books/NBK278923/</mixed-citation><mixed-citation xml:lang="en">Walker MD, Bilezikian JP. Primary Hyperparathyroidism. Endotext [Internet]. South Dartmouth (MA); 2021 [updated 2021 Apr 19, cited 2022 Mar 28]. Available online: https://www.ncbi.nlm.nih.gov/books/NBK278923/</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Khan AA, Hanley DA, Rizzoli R, et al. Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. Osteoporos Int 2017;28:1–19.</mixed-citation><mixed-citation xml:lang="en">Khan AA, Hanley DA, Rizzoli R, et al. Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. Osteoporos Int 2017;28:1–19.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Cheung K, Wang TS, Farrokhyar F, et al. A metaanalysis of preoperative localization techniques for patients with primary hyperparathyroidism. Ann Surg Oncol 2012;19:577–83.</mixed-citation><mixed-citation xml:lang="en">Cheung K, Wang TS, Farrokhyar F, et al. A metaanalysis of preoperative localization techniques for patients with primary hyperparathyroidism. Ann Surg Oncol 2012;19:577–83.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Kunstman JW, Kirsch JD, Mahajan A, Udelsman R. Clinical review: Parathyroid localization and implications for clinical management. J Clin Endocrinol Metab 2013;98:902–12.</mixed-citation><mixed-citation xml:lang="en">Kunstman JW, Kirsch JD, Mahajan A, Udelsman R. Clinical review: Parathyroid localization and implications for clinical management. J Clin Endocrinol Metab 2013;98:902–12.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Noureldine SI, Aygun N, Walden MJ, et al. Multiphase computed tomography for localization of parathyroid disease in patients with primary hyperparathyroidism: How many phases do we really need? Surgery 2014;156:1300–6; discussion 1306–7.</mixed-citation><mixed-citation xml:lang="en">Noureldine SI, Aygun N, Walden MJ, et al. Multiphase computed tomography for localization of parathyroid disease in patients with primary hyperparathyroidism: How many phases do we really need? Surgery 2014;156:1300–6; discussion 1306–7.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Yeh R, Tay YD, Tabacco G, et al. Diagnostic Performance of 4D CT and Sestamibi SPECT/ CT in Localizing Parathyroid Adenomas in Primary Hyperparathyroidism. Radiology 2019;291:469–76.</mixed-citation><mixed-citation xml:lang="en">Yeh R, Tay YD, Tabacco G, et al. Diagnostic Performance of 4D CT and Sestamibi SPECT/ CT in Localizing Parathyroid Adenomas in Primary Hyperparathyroidism. Radiology 2019;291:469–76.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Beheshti M, Hehenwarter L, Paymani Z, et al. (18)F-Fluorocholine PET/CT in the assessment of primary hyperparathyroidism compared with (99m)TcMIBI or (99m)Tc-tetrofosmin SPECT/CT: a prospective dual-centre study in 100 patients. Eur J Nucl Med Mol Imaging 2018;45:1762–71.</mixed-citation><mixed-citation xml:lang="en">Beheshti M, Hehenwarter L, Paymani Z, et al. (18)F-Fluorocholine PET/CT in the assessment of primary hyperparathyroidism compared with (99m)TcMIBI or (99m)Tc-tetrofosmin SPECT/CT: a prospective dual-centre study in 100 patients. Eur J Nucl Med Mol Imaging 2018;45:1762–71.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Habener JF, Maunus R, Dee PC, Potts JT Jr. Early events in the cellular formation of proparathyroid hormone. J Cell Biol 1980;85:292–8.</mixed-citation><mixed-citation xml:lang="en">Habener JF, Maunus R, Dee PC, Potts JT Jr. Early events in the cellular formation of proparathyroid hormone. J Cell Biol 1980;85:292–8.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Hellman P, Ahlström H, Bergström M, et al. Positron emission tomography with 11C-methionine in hyperparathyroidism. Surgery 1994;116:974–81.</mixed-citation><mixed-citation xml:lang="en">Hellman P, Ahlström H, Bergström M, et al. Positron emission tomography with 11C-methionine in hyperparathyroidism. Surgery 1994;116:974–81.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Beggs AD, Hain SF. Localization of parathyroid adenomas using 11C-methionine positron emission tomography. Nucl Med Commun 2005;26:133–6.</mixed-citation><mixed-citation xml:lang="en">Beggs AD, Hain SF. Localization of parathyroid adenomas using 11C-methionine positron emission tomography. Nucl Med Commun 2005;26:133–6.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Braeuning U, Pfannenberg C, Gallwitz B, et al. 11C-methionine PET/CT after inconclusive 99mTc-MIBISPECT/CT for localisation of parathyroid adenomas in primary hyperparathyroidism. Nuklearmedizin 2015;54:26–30.</mixed-citation><mixed-citation xml:lang="en">Braeuning U, Pfannenberg C, Gallwitz B, et al. 11C-methionine PET/CT after inconclusive 99mTc-MIBISPECT/CT for localisation of parathyroid adenomas in primary hyperparathyroidism. Nuklearmedizin 2015;54:26–30.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Mallikarjuna VJ, Mathew V, Ayyar V, et al. Five-year Retrospective Study on Primary Hyperparathyroidism in South India: Emerging Roles of Minimally Invasive Parathyroidectomy and Preoperative Localization with Methionine Positron Emission TomographyComputed Tomography Scan. Indian J Endocrinol Metab 2018;22:355–61.</mixed-citation><mixed-citation xml:lang="en">Mallikarjuna VJ, Mathew V, Ayyar V, et al. Five-year Retrospective Study on Primary Hyperparathyroidism in South India: Emerging Roles of Minimally Invasive Parathyroidectomy and Preoperative Localization with Methionine Positron Emission TomographyComputed Tomography Scan. Indian J Endocrinol Metab 2018;22:355–61.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Maccora D, Caldarella C, Calcagni ML. (11) C-Methionine PET/CT in patients with primary hyperparathyroidism and inconclusive pre-operative imaging work-up: diagnostic accuracy and role of semiquantitative analysis. Ann Nucl Med 2021;35:469–78.</mixed-citation><mixed-citation xml:lang="en">Maccora D, Caldarella C, Calcagni ML. (11) C-Methionine PET/CT in patients with primary hyperparathyroidism and inconclusive pre-operative imaging work-up: diagnostic accuracy and role of semiquantitative analysis. Ann Nucl Med 2021;35:469–78.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Chun IK, Cheon GJ, Paeng JC, et al. Detection and Characterization of Parathyroid Adenoma/Hyperplasia for Preoperative Localization: Comparison Between (11)C-Methionine PET/CT and (99m)Tc-Sestamibi Scintigraphy. Nucl Med Mol Imaging 2013;47:166–72.</mixed-citation><mixed-citation xml:lang="en">Chun IK, Cheon GJ, Paeng JC, et al. Detection and Characterization of Parathyroid Adenoma/Hyperplasia for Preoperative Localization: Comparison Between (11)C-Methionine PET/CT and (99m)Tc-Sestamibi Scintigraphy. Nucl Med Mol Imaging 2013;47:166–72.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Tang BN, Moreno-Reyes R, Blocklet D, et al. Accurate pre-operative localization of pathological parathyroid glands using 11C-methionine PET/CT. Contrast Media Mol Imaging 2008;3:157–63.</mixed-citation><mixed-citation xml:lang="en">Tang BN, Moreno-Reyes R, Blocklet D, et al. Accurate pre-operative localization of pathological parathyroid glands using 11C-methionine PET/CT. Contrast Media Mol Imaging 2008;3:157–63.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Mokrysheva NG, Eremkina AK, Mirnaya SS, et al. The clinical practice guidelines for primary hyperparathyroidism, short version. Probl Endokrinol (Mosk) 2021;67:94–124. In Russian [Мокрышева Н.Г., Еремкина А.К., Мирная С.С. и др. Клинические рекомендации по первичному гиперпаратиреозу, краткая версия. Проблемы Эндокринологии. 2021;67(4):94– 124].</mixed-citation><mixed-citation xml:lang="en">Mokrysheva NG, Eremkina AK, Mirnaya SS, et al. The clinical practice guidelines for primary hyperparathyroidism, short version. Probl Endokrinol (Mosk) 2021;67:94–124. In Russian [Мокрышева Н.Г., Еремкина А.К., Мирная С.С. и др. Клинические рекомендации по первичному гиперпаратиреозу, краткая версия. Проблемы Эндокринологии. 2021;67(4):94– 124].</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Hoang JK, Sung WK, Bahl M, Phillips CD. How to perform parathyroid 4D CT: tips and traps for technique and interpretation. Radiology 2014;270:15–24.</mixed-citation><mixed-citation xml:lang="en">Hoang JK, Sung WK, Bahl M, Phillips CD. How to perform parathyroid 4D CT: tips and traps for technique and interpretation. Radiology 2014;270:15–24.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Kuzminski SJ, Sosa JA, Hoang JK. Update in Parathyroid Imaging. Magn Reson Imaging Clin N Am 2018;26:151–66.</mixed-citation><mixed-citation xml:lang="en">Kuzminski SJ, Sosa JA, Hoang JK. Update in Parathyroid Imaging. Magn Reson Imaging Clin N Am 2018;26:151–66.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
